Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | SMYD2 | Q9NRG4 | 2/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5724518 | 0.95 | CYP3A4 (0.34) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL16633342 | 0.95 | CYP3A4 (0.34) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL5826953 | 0.92 | CYP3A4 (0.34) | CYP3A4HTTSMN1; SMN2SMYD2EPHX1 | |
| SCHEMBL5727045 | 0.88 | CYP3A4 (0.36) | CYP3A4HTTSMN1; SMN2SMYD2EPHX1 | |
| SCHEMBL5826670 | 0.86 | AAK1 (0.36) | CYP3A4HTTSMN1; SMN2SMYD2EPHX1 | |
| SCHEMBL5724098 | 0.85 | SMYD2 (0.37) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL5826505 | 0.85 | SMYD2 (0.32) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL20212164 | 0.84 | SIGMAR1 (0.34) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL20212163 | 0.84 | SIGMAR1 (0.34) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL5724483 | 0.82 | SCN4A (0.36) | CYP3A4HTTSMN1; SMN2SMYD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1340757-B1 | 1-METHYLCARBAPENEM DERIVATIVES | SANKYO CO (JP) | 2006-10-11 | — | — | EP | disclosed |
| US-7001897-B2 | 1-methylcarbapenem derivatives | SANKYO COMPANY, LIMITED (JP) | 2006-02-21 | — | — | US | disclosed |
| US-20040014962-A1 | 1-Methylcarbapenem derivatives | SANKYO COMPANY, LIMITED (JP) | 2004-01-22 | — | — | US | disclosed |
| EP-1340757-A1 | 1-METHYLCARBAPENEM DERIVATIVES | Sankyo Company, Limited (JP) | 2003-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014962-A1 | 1-Methylcarbapenem derivatives | CD14, CPT1A, ACMSD | CYP3A4 69/4885HTT 4456/4885SMN1; SMN2 1508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.